Although the pathway inhibits the activation of AKT, which is a downstream component of BCR-ABL pathway, it also leads to release of inhibitory sequestration of FOXO, which promotes quiescence in CML stem cells, and ultimately results in TKI resistance25, 26. Here, AKT1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.